Abstract: Compounds are provided for use with glucokinase that comprise the formula: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.

Abstract: Compounds are provided for use with kinases that comprise (I), (II), (III), (IV): wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.

Abstract: Provided are crystals relating to Farsenyl Pvrophosphate Synthase (IspA) from E. coli and its various uses.

Abstract: Provided are crystals relating to human phosphodiesterase 4-D3 (PDE4-D3), methods for forming crystals comprising PDE4-D3 and crystals comprising PDE4-D3 co-crystallized with a ligand molecule, and methods of using crystals comprising PDE4-D3.

Abstract: Compounds are provided for use with kinases that comprise a compound selected from the group consisting of: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.

Abstract: Provided are crystals relating to the carboxyltransferase domain of human Acetyl-Coenzyme A Carboxylase 2 and its various uses.

Abstract: Compounds are provided for use with glucokinase that comprise the formula: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.

Abstract: A crystallization system is provided comprising a trial generation station configured to generate crystallization trials in trial zones of a crystallization plate; an imaging station configured to take images of crystallization trials in the crystallization plate; a transport mechanism configured to transport the crystallization plate to the imaging station after generation of the crystallization trials; and a controller including logic for causing the trial generation station to generate the crystallization trials in the crystallization plate, logic for causing the transport mechanism to transport the crystallization plate to the imaging station and logic for causing the imaging station to take images of the crystallization trials.

Abstract: Provided are crystals relating to histone deacetylase 2 (HDAC-2) and its various uses.

Abstract: A method is provided for operating a crystallization system comprising identifying a screen storage plate from among the plurality of screen storage plates stored in a screen storage station, each screen storage plate having a plurality of wells that contain a screen solution and at least a portion of the screen storage plates having a selection of screen solutions that is different from the selection of screen solutions held in other screen storage plates; having a transport mechanism transport the identified screen storage plate to a screen replicator; transporting a plurality of crystallization plates to the screen replicators; and having the screen replicator transfer the screen solutions from the identified screen storage plate to the plurality of crystallization plates.

Abstract: Provided are crystals relating to Aurora/LPL1P-related kinase and its various uses.

Abstract: A trial generation station is provided comprising: a deck configured to receive a crystallization plate from a transport mechanism, the crystallization plate including a plurality of trial zones where crystallization trials are generated; and a head configured to be moved relative to the stage, the head including a plurality of primary fluid dispensers, each fluid dispenser being configured to transfer a portion of a mother liquor from the well region of a trial zone to a sample region associated with the trial zone, and one or more secondary fluid dispensers configured to dispense a molecule solution into the sample regions of the wells, the molecule solution including the molecule to be crystallized by the system and at least one of the secondary fluid dispenser being laterally immobilized relative to one or more of the fluid dispensers.

Abstract: A crystallization system is provided comprising a screen generation station; a screen storage station; including a housing configured to store a plurality of screen storage plates and mechanics for retrieving a selected screen storage plate from among the plurality of screen storage plates for transport to another station a transport mechanism configured to transport a screen storage plate containing the screen solutions generated at the screen generation station to the screen storage station; and a controller.

Abstract: A method is provided that comprises generating a screen storage plate that contains screen solutions at a screen generation station; employing a transport mechanism to transport the screen storage plate from the screen generation station to a screen storage station; storing the screen storage plate in the screen storage station among a plurality of screen storage plates; having the screen storage station retrieve screen storage plate from among the plurality of screen storage plates stored within the screen storage station; and having a crystallization trial generation station generate crystallization trials in a crystallization plate incorporating the screen in the retrieved screen storage plate; wherein the method is performed in a single automated system.

Abstract: A crystallization system is provided comprising: a screen replicator configured to transfer screen solutions from wells of a screen storage plate into well regions of multiple crystallization plates; a trial generation station configured to generate crystallization trials in the trial zones of a crystallization plate; a transport mechanism configured to transport crystallization plates from the screen replicator to the trial generation station; and a controller having logic for causing the screen replicator to transfer the screen solutions from the screen storage plate to multiple crystallization plates, logic for causing the transport mechanism to transport the crystallization plates from the screen replicator to the trial generation station and logic for causing the trial generation station to generate crystallization trials in the crystallization plates.

Abstract: A microfluidic method is provided that comprises: delivering a first fluid to a first lumen of a microfluidic device and a second, different fluid to a second lumen of the microfluidic device, the first and second lumens sharing a common wall which allows for diffusion between the lumens over at least a portion of the length of the lumens; and having the first and second fluids diffuse between the first and second lumens.

Abstract: A method is provided that comprises having a trial generation station generate crystallization trials in a crystallization plate transporting the crystallization plate to an imaging station; and having the imaging station take images of the crystallization trials within 30 minutes of the formation of the crystallization trials; wherein the method is performed in a single automated system.

Abstract: A crystallization system is provided that comprises a screen replicator having a transfer mechanism configured to transfer portions of different screen solutions contained in a screen storage plate to well regions of a crystallization plate; a screen storage station including a housing configured to store a plurality of screen storage plates and mechanics for retrieving a selected screen storage plate from among the plurality of screen storage plates for transport to the screen replicator; a transport mechanism configured to transport a screen storage plate retrieved by the screen storage station to the screen replicator; and a controller including logic for causing the screen storage station to retrieve the selected screen storage plate from among the plurality of screen storage plates, logic for causing the transport mechanism to transport the selected screen storage plate from the screen storage station to the screen replicator, and logic for causing the screen replicator to transfer portions of different

Abstract: Histone deacetylase inhibitors and uses thereof are provided that have the general formula wherein R1, R2, R3 and R4 are each independently selected from the group consisting of hydrogen, a substituted or unsubstituted straight chained C1-12 alkyl, C2-12 aminoalkyl or C2-12 oxaalkyl, and a substituted and unsubstituted 3, 4, 5, 6, 7 or 8 membered ring, with the proviso that R3 and R4 are not both hydrogen; R5 is selected from the group consisting of a carbonyl, a substituted or unsubstituted C1-3 alkyl, a substituted or unsubstituted —C1-3 alkyl-C(O), a substituted or unsubstituted —C(O)—C1-3 alkyl, and a substituted or unsubstituted —C(O)C(O)C1-3 alkyl; M is a substituent capable of complexing with a protein metal ion; and L is a substituent comprising a chain of 3-12 atoms connecting the M substituent to the carbon atom alpha to the L substituent.

Abstract: Compounds that may be used to inhibit histone deacetylase having the formula Z-Q-L-M or Z-L-M wherein M is a substituent capable of complexing with a deacetylase catalytic site and/or a metal ion; L is a substituent providing between 0-10 atoms separation between the M substituent and the remainder of the compound; and Z and Q are as defined herein.